Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2025-10-12
DOI
https://doi.org/10.1080/14796694.2025.2565877
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia

Rami S. Komrokji
Future Oncology
Acute Myeloid Leukemia Research
article

Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia

Rami S. Komrokji
article en

Abstract

No abstract available for this paper.
Future OncologyVol. 21(25)
Moffitt Cancer Center (US)
Openalex Percentile: Top 63%
Acute Myeloid Leukemia Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia — Rami S. Komrokji · Future Oncology (2025) | TGRS Research Map | TGRS